ZA200902409B - Lingo binding molecules and pharmaceutical use thereof - Google Patents

Lingo binding molecules and pharmaceutical use thereof

Info

Publication number
ZA200902409B
ZA200902409B ZA200902409A ZA200902409A ZA200902409B ZA 200902409 B ZA200902409 B ZA 200902409B ZA 200902409 A ZA200902409 A ZA 200902409A ZA 200902409 A ZA200902409 A ZA 200902409A ZA 200902409 B ZA200902409 B ZA 200902409B
Authority
ZA
South Africa
Prior art keywords
binding molecules
pharmaceutical use
lingo binding
lingo
pharmaceutical
Prior art date
Application number
ZA200902409A
Other languages
English (en)
Inventor
Adrien Walmsley
William Leonard Wishart
Marta Cortes-Cros
Josef Prassler
Ingo Klagge
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38325542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200902409(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200902409B publication Critical patent/ZA200902409B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200902409A 2006-11-17 2009-04-07 Lingo binding molecules and pharmaceutical use thereof ZA200902409B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06124350 2006-11-17

Publications (1)

Publication Number Publication Date
ZA200902409B true ZA200902409B (en) 2010-04-28

Family

ID=38325542

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200902409A ZA200902409B (en) 2006-11-17 2009-04-07 Lingo binding molecules and pharmaceutical use thereof

Country Status (27)

Country Link
US (4) US8299221B2 (pt)
EP (2) EP2084190B1 (pt)
JP (2) JP5647414B2 (pt)
KR (1) KR20090078353A (pt)
CN (2) CN103351437A (pt)
AR (1) AR063829A1 (pt)
AT (1) ATE502960T1 (pt)
AU (1) AU2007321817A1 (pt)
BR (1) BRPI0718406A2 (pt)
CA (1) CA2669181A1 (pt)
CL (1) CL2007003303A1 (pt)
CO (1) CO6180433A2 (pt)
CR (1) CR10756A (pt)
DE (1) DE602007013445D1 (pt)
EC (1) ECSP099332A (pt)
ES (1) ES2363622T3 (pt)
GT (1) GT200900121A (pt)
IL (1) IL198313A0 (pt)
MA (1) MA30965B1 (pt)
MX (1) MX2009005175A (pt)
NO (1) NO20092331L (pt)
PE (1) PE20081392A1 (pt)
RU (1) RU2009122514A (pt)
TN (1) TN2009000190A1 (pt)
TW (1) TW200831534A (pt)
WO (1) WO2008058736A1 (pt)
ZA (1) ZA200902409B (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA010055B1 (ru) 2003-03-19 2008-06-30 Байоджен Айдек Ма Инк. ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА, КОДИРУЮЩАЯ ПОЛИПЕПТИД Sp35, ПОЛИПЕПТИД Sp35 И СПОСОБЫ ПРИМЕНЕНИЯ НУКЛЕИНОВОЙ КИСЛОТЫ И ПОЛИПЕПТИДА
KR101239542B1 (ko) 2004-06-24 2013-03-07 바이오겐 아이덱 엠에이 인코포레이티드 탈수초화를 수반하는 병의 치료
WO2007008547A2 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
NZ598421A (en) * 2005-12-02 2013-11-29 Biogen Idec Inc Treatment of Conditions Involving Demyelination
JP2009544703A (ja) 2006-07-24 2009-12-17 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｐ３５またはＴｒｋＡアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US20100297121A1 (en) * 2007-10-11 2010-11-25 Biogen Idec Ma Inc. Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of LINGO-1 Antagonists and TrkB Agonists
US20110123553A1 (en) * 2007-11-08 2011-05-26 Biogen Idec Ma Inc. Use of LINGO-4 Antagonists in the Treatment of Conditions Involving Demyelination
NZ590605A (en) 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
AU2011248625B2 (en) 2010-04-26 2017-01-05 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
CN108165537A (zh) 2010-04-27 2018-06-15 Atyr医药公司 与苏氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2797362C (en) 2010-04-27 2020-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
CA2797271C (en) 2010-04-28 2021-05-25 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
AU2011248490B2 (en) 2010-04-29 2016-11-10 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
AU2011248457B2 (en) 2010-04-29 2017-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases
CA2797277C (en) 2010-05-03 2021-02-23 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
US9034321B2 (en) 2010-05-03 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
EP2566516B1 (en) 2010-05-03 2019-07-03 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-trna synthetases
EP2566496B1 (en) 2010-05-03 2018-02-28 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
AU2011248101B2 (en) 2010-05-04 2016-10-20 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
CA2798301C (en) 2010-05-04 2020-09-15 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutamyl-prolyl-trna synthetases
CA2799197C (en) 2010-05-14 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
AU2011256366C1 (en) 2010-05-17 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
JP6046607B2 (ja) 2010-05-27 2016-12-21 エータイアー ファーマ， インコーポレイテッド グルタミニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2011153277A2 (en) 2010-06-01 2011-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
US8969301B2 (en) 2010-07-12 2015-03-03 Atyr Pharma Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-tRNA synthetases
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
AU2011289833C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Histidyl-tRNA synthetases
EP2608801B1 (en) 2010-08-25 2019-08-21 aTyr Pharma, Inc. INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
JP6039566B2 (ja) 2010-10-06 2016-12-07 エータイアー ファーマ， インコーポレイテッド 治療用、診断用および抗体組成物に関連したトリプトファニルｔＲＮＡ合成酵素のタンパク質フラグメントの革新的発見
WO2013022982A2 (en) 2011-08-09 2013-02-14 Atyr Pharma, Inc. Pegylated tyrosyl-trna synthetase polypeptides
US9822353B2 (en) 2011-12-06 2017-11-21 Atyr Pharma, Inc. PEGylated aspartyl-tRNA synthetase polypeptides
US9816084B2 (en) 2011-12-06 2017-11-14 Atyr Pharma, Inc. Aspartyl-tRNA synthetases
WO2013115926A2 (en) 2011-12-29 2013-08-08 Atyr Pharma, Inc. Aspartyl-trna synthetase-fc conjugates
US9248128B2 (en) 2012-01-27 2016-02-02 New York University Method for enhancing remyelination using GLI1 inhibitors
MX2014013950A (es) * 2012-05-14 2015-02-17 Biogen Idec Inc Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
DK3460054T3 (da) 2013-03-15 2021-01-18 Atyr Pharma Inc Histidyl-tRNA-syntetase-Fc-konjugater
EP3242893A1 (en) 2015-01-08 2017-11-15 Biogen MA Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
WO2016122761A1 (en) * 2015-01-26 2016-08-04 Intel IP Corporation Device and method to improve horizontal and vertical positioning accuracy
JP7149257B2 (ja) * 2016-07-13 2022-10-06 バイオジェン・エムエイ・インコーポレイテッド Ｌｉｎｇｏ－１アンタゴニストの投与計画及び脱髄障害の処置のための使用
CA3060514A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
KR102414826B1 (ko) 2020-06-18 2022-06-30 삼성전기주식회사 코일 부품

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308573D0 (en) 1983-03-29 1983-05-05 British Nuclear Fuels Ltd Filament impregnating/coating
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO1990009438A1 (en) 1989-02-13 1990-08-23 Schering Aktiengesellschaft Berlin Und Bergkamen Novel thrombolytic
ES2352551T3 (es) * 2003-03-19 2011-02-21 Biogen Idec Ma Inc. Proteína de unión a receptor nogo.
EA010055B1 (ru) 2003-03-19 2008-06-30 Байоджен Айдек Ма Инк. ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА, КОДИРУЮЩАЯ ПОЛИПЕПТИД Sp35, ПОЛИПЕПТИД Sp35 И СПОСОБЫ ПРИМЕНЕНИЯ НУКЛЕИНОВОЙ КИСЛОТЫ И ПОЛИПЕПТИДА
US20050214288A1 (en) * 2004-03-26 2005-09-29 Human Genome Sciences, Inc. Antibodies against Nogo receptor
KR101239542B1 (ko) * 2004-06-24 2013-03-07 바이오겐 아이덱 엠에이 인코포레이티드 탈수초화를 수반하는 병의 치료
WO2007008547A2 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof

Also Published As

Publication number Publication date
WO2008058736A1 (en) 2008-05-22
AR063829A1 (es) 2009-02-18
PE20081392A1 (es) 2008-11-12
US20140255415A1 (en) 2014-09-11
JP2010509906A (ja) 2010-04-02
GT200900121A (es) 2011-11-11
ECSP099332A (es) 2009-06-30
US20100143362A1 (en) 2010-06-10
ATE502960T1 (de) 2011-04-15
US8299221B2 (en) 2012-10-30
MA30965B1 (fr) 2009-12-01
TN2009000190A1 (en) 2010-10-18
CL2007003303A1 (es) 2008-06-27
JP2013056888A (ja) 2013-03-28
CN103351437A (zh) 2013-10-16
DE602007013445D1 (de) 2011-05-05
US20140037639A1 (en) 2014-02-06
CA2669181A1 (en) 2008-05-22
EP2395022A9 (en) 2013-04-24
CN101553506A (zh) 2009-10-07
CN101553506B (zh) 2013-08-07
US20130071400A1 (en) 2013-03-21
IL198313A0 (en) 2011-08-01
EP2084190A1 (en) 2009-08-05
BRPI0718406A2 (pt) 2013-12-17
EP2395022A1 (en) 2011-12-14
CO6180433A2 (es) 2010-07-19
RU2009122514A (ru) 2010-12-27
CR10756A (es) 2009-06-04
TW200831534A (en) 2008-08-01
EP2084190B1 (en) 2011-03-23
ES2363622T3 (es) 2011-08-10
KR20090078353A (ko) 2009-07-17
JP5647414B2 (ja) 2014-12-24
MX2009005175A (es) 2009-08-07
AU2007321817A1 (en) 2008-05-22
NO20092331L (no) 2009-06-17

Similar Documents

Publication Publication Date Title
ZA200902409B (en) Lingo binding molecules and pharmaceutical use thereof
GB0621973D0 (en) Binding molecules and uses thereof
EP2041180A4 (en) ILT3 BINDING MOLECULES AND USES THEREOF
IL206356A0 (en) Improved fibronectin-based binding molecules and their use
GB0601513D0 (en) Binding molecules 3
HK1112005A1 (en) Gitr binding molecules and uses therefor
ZA200900494B (en) DNA Molecules and methods
IL195675A0 (en) Human binding molecules having killing activity against staphylococci and uses thereof
EP2268813A4 (en) RNA MOLECULES AND THEIR USE
IL194751A0 (en) Drugs and uses
EP2136846A4 (en) THERAPEUTIC OBJECTIVES AND MOLECULES
ZA200901815B (en) Binding molecules
HK1136160A1 (en) Disintegrin variants and pharmaceutical uses thereof
PL2064327T3 (pl) Dbait i ich zastosowania
EP2005171A4 (en) SERUM INHIBITORY INFLAMMATORY FACTORS AND USES THEREOF
GB0516069D0 (en) Pharmaceutical and use thereof
IL193700A0 (en) Medicaments and proteins
HK1136819A1 (en) Novel dithiolopyrrolones and their therapeutic applications
HK1133552A1 (en) Carboranylporphyrins and uses thereof
EP2077262A4 (en) IMINOPYRIDINE DERIVATIVES AND THEIR USE
EP1966603A4 (en) FIXING MOLECULES
HK1143597A1 (en) Improved nogo-a binding molecules and pharmaceutical use thereof
EP2117519A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF TRAMADOL AND KETOPROFEN
GB0601511D0 (en) Binding Molecules 2
EP2097085A4 (en) THERAPEUTIC MATERIALS AND METHOD